Multi-site study shows personalized ctDNA analysis is highly prognostic of recurrence-free survival and outperforms CA-125 in identifying patients at high risk of recurrence
AUSTIN, Texas, Oct. 6,. | October 6, 2022
/PRNewswire/ Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of the latest data from the.
/PRNewswire/ Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of its 2021 Environmental,.
/PRNewswire/ Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Steve Chapman, chief executive officer, and Mike.